SYDNEY, April 2, 2015 /PRNewswire/ -- Novogen Ltd
(ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based
public relations firm, PCG Advisory (PCG), to drive the Company's
investor-awareness program in the US. PCG will be using their
expertise in creating awareness and establishing key relationships
within the US investment community via their targeted outreach
campaign.
Dr Graham Kelly said: "The investment community has reacted
positively in recent times to the Company's extensive drug
discovery program and with significant growth in activity ahead in
the short-term, we felt it was timely to appoint an advisory firm
to build on that momentum and communicate our activities to the
market to maximise shareholder value. Showcasing the Company
to the wholesale investment community is a key part of our strategy
to bring new investors into the stock through on-market buying. We
look forward to working with the PCG team."
Jeff Ramson, Founder and CEO of
PCG stated, "We are excited to work with the entire team at
Novogen. We have extensive experience with Australian
emerging growth companies that have stakeholders on several
continents. We look forward to communicating the Novogen
story to a larger group of US investors, who need to learn about
their drug technology platforms and how management will execute the
Company's strategy in the short and long term. We look forward to
the partnership."
ABOUT PCG ADVISORY GROUP
Founded in 2008, PCG Advisory Group is dedicated to the delivery
of top tier capital markets advisory services, strategic investor
relations, tactical digital and social media communications and
cutting edge media and public relations for public and privately
held companies. The team at PCG has extensive experience with life
sciences and healthcare, high technology, metals and mining,
financial services and emerging growth companies from around the
globe.
PCG's Capital Markets Advisory Services include overall investor
relations' strategy development to increase and leverage investor
awareness, visibility and credibility. PCG's Social and Digital
Media services include leveraging social and professional digital
media sites to effectively and accurately communicate client
stories. As an aggregation, distribution, and engagement platform,
PCG reaches thousands of individual, retail, institutional
investors, bankers and analysts using proprietary techniques,
search engine optimization, online marketing, website development
and our proprietary and extensive distribution network. PCG's Media
and Public Relations services are a strategic and integral
component of all Corporate Communications. The media and public
relations team works with print, broadcast, online news sites and
bloggers to communicate the best client story at the right time.
PCG also actively assists clients during the pre- and post-IPO process as well as through mergers,
acquisitions, uplistings, and or a potential crisis. Communicating
the client's story accurately and effectively is tantamount to
maximizing exposure to its current and potential stakeholders.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade
on both the Australian Securities Exchange ('NRT') and NASDAQ
('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc.,
with Yale University.
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM
compounds target the microfilament component of the cancer cell and
when used in conjunction with standard anti-microtubule drugs,
result in comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant
ascites, prostate cancer, neural cancers (glioblastoma,
neuroblastoma in children) and melanoma are the key clinical
indications being pursued, with the ultimate objective of employing
both technologies as a unified approach to first-line therapy.
Further information is available on our websites
www.novogen.com
For more information please contact:
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4100
|
Media
Enquiries
Cristyn
Humphreys
Chief Operating
Officer
Novogen
Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472
4111
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-engages-leading-us-investor-relations-firm-300060009.html
SOURCE Novogen Ltd